Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.

PLoS neglected tropical diseases - 1 Nov 2016

Dauchy Frédéric-Antoine, Bonhivers Mélanie, Landrein Nicolas, Dacheux Denis, Courtois Pierrette, Lauruol Florian, Daulouède Sylvie, Vincendeau Philippe, Robinson Derrick R

Abstract excerpt

Trypanosoma brucei gambiense is the main causative agent of Human African Trypanosomiasis (HAT), also known as sleeping sickness. Because of limited alternatives and treatment toxicities, new therapeutic options are urgently needed for patients with HAT. Sterol 14alpha-demethylase (CYP51) is a potential drug target but its essentiality has not been determined in T. brucei. We used a tetracycline-inducible RNAi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokinesis
Share to Doxycycline

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ergosterol

Share to Sterol 14-Demethylase

Share to Triazoles

Share to Trypanocidal Agents

Share to Trypanosoma brucei brucei

Share to Trypanosomiasis, African

Source

Open in PubMed Open full text

Identifiers

PMID: 27855164
DOI: 10.1371/journal.pntd.0005125
PMCID: PMC5113867

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.PMID 27855164Read ↗

Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.Semantic proximity Read ↗

Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?Semantic proximity Read ↗

Biodiversity of CYP51 in trypanosomes.Semantic proximity Read ↗

Targeting Ergosterol Biosynthesis in Leishmania donovani: Essentiality of Sterol 14alpha-demethylaseSemantic proximity Read ↗

CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase.Semantic proximity Read ↗

A <i>Trypanosoma brucei</i> ORFeome-based Gain-of-Function Library identifies genes that promote survival during melarsoprol treatmentSemantic proximity Read ↗

Targeting the nucleotide metabolism of Trypanosoma brucei and other trypanosomatidsSemantic proximity Read ↗

Complete In Vitro Life Cycle of Trypanosoma congolense: Development of Genetic ToolsSemantic proximity Read ↗

Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug DiscoverySemantic proximity Read ↗

A <i>Trypanosoma brucei</i> ORFeome-based Gain-of-Function Library reveals novel genes associated with melarsoprol resistanceSemantic proximity Read ↗

Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in miceSemantic proximity Read ↗

The critical role of mode of action studies in kinetoplastid drug discoverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.